Navigation Links
King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acura's Aversion(R) (Abuse-Deterrent) Technology
Date:10/31/2007

the License, Development and Commercialization Agreement

The Agreement provides King with an exclusive license in the Territory for ACUROX(TM) Tablets (formerly OxyADF) and another undisclosed opioid product utilizing Acura's Aversion(R) Technology. In addition, the Agreement provides King with an option to license in the Territory all future opioid analgesic products developed utilizing Acura's Aversion(R) Technology.

Under the terms of the Agreement, King will make an upfront cash payment to Acura of $30 million. Depending on the achievement of certain development and regulatory milestones, King could also make additional cash payments to Acura of up to $28 million relating to ACUROX(TM) Tablets and similar amounts with respect to each subsequent Aversion(R) Technology product developed under the Agreement. King will reimburse Acura for all research and development expenses incurred beginning from September 19, 2007 for ACUROX(TM) Tablets and all research and development expenses related to future products after King's exercise of its option to an exclusive license for each future product. King will record net sales of all products and pay Acura a royalty ranging from 5% to 25% based on the level of combined annual net sales for all products subject to the Agreement. King will also make a one-time cash payment to Acura of $50 million in the first year in which the combined annual net sales of all products exceed $750 million.

King and Acura will form a joint steering committee to coordinate development and commercialization strategies. With King's oversight, Acura will conduct all ACUROX(TM) Tablet development activities through approval of a New Drug Application ("NDA") and thereafter King will commercialize ACUROX(TM) in the U.S. With respect to all other products subject to the Agreement, King will be responsible for development and regulatory activities following either acceptance of an Investigational New Drug Application by the U.S. Food a
'/>"/>

SOURCE King Pharmaceuticals, Inc.; Acura Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)... Finding might one day lead to a novel technique t...AY, Nov. 21 (HealthDay News) -- Belgian researcher...c acid instead of sugar for food, and this might l...ells. , To survive and proliferate, all cells i... burning sugar [glucose], a process that requires ...
(Date:11/21/2008)... 11.4% Shareholders Intend To Vigorously Protect I... CINCINNATI, Nov. 21 Dr...y filed an amendment to their Schedule 13D with th...oup previously filed a 13D disclosing ownership of...h operates 77 LasikPlus fixed-site laser vision co...
(Date:11/21/2008)... MONTVALE, N.J., Nov. 21 ...nnounced that its shareholders overwhelmingly appr...he acquisition of Barr by Teva Pharmaceuticals Ind...,s vote demonstrated the overwhelming support of t...ce L. Downey, Barr,s Chairman and CEO. "We are ple...
(Date:11/21/2008)... DALLAS, Nov. 21 In a statewide su...e Texas Institute for Surgery at Presbyterian Hosp...its 2008 annual listing of " Super Doctors ." , ... work with Key Professional Media, Inc. to survey... state of Texas to ask, "If you needed medical car...
Breaking Medicine News(10 mins):Health News:New Approach Keeps Tumor Cells From Refueling 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 3Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 4Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 5Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 6Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 7Health News:Barr Shareholders Approve Pending Teva Acquisition 2Health News:Barr Shareholders Approve Pending Teva Acquisition 3Health News:Barr Shareholders Approve Pending Teva Acquisition 4Health News:Annual List of 'Super Doctors' Features 33 Texas Institute for Surgery Physicians 2
...aunching a cancer-fighting tomato. The supermarket...the Vine is lycopene-rich to the tune of almost tw...the chemical that gives red color to the tomatoes ...osed to fight prostate cancer, breast cancer and c...
...o was convicted of murdering Lin Russell and her s... publication of a report that probes the failure o...ng spree. // The independent report by Robert Fran...nce it was published six years ago after many appe...
...officials confirmed that a poultry worker in West ...ing the number of human cases in Indonesia to 33//...eceived the confirmation from WHO Tuesday morning,...eral of animal-borne disease control at the Indone...
...es like New York are sometimes good from far but f..., money, opportunity and over all a good life// , ...ts residents. According to a latest survey, New Yo... lot compared to the other parts of United States....
Other Medicine News:
(Date:11/20/2008)...November 20 Arpida (SWX:...ugs Advisory Committee of the,U.S. Food and Drug ...,approval of intravenous iclaprim, an antibiotic ...ients with complicated skin and skin structure inf...cillin-resistant Staphylococcus,aureus (MRSA). ,...
(Date:11/20/2008)...0 Bionovo, Inc.,(Nasdaq...lts from the Phase 1B,clinical trial of their lea...ancer, BZL101, at the Society for Integrative Onco... Georgia. The Company,s oral presentation was sel...nted as a part of the Best of the,SIO Session on ...
(Date:11/20/2008)... Radius Health ("Radius") announced...n to its second institutional financing round, inc... and the total amount raised since the company,s i...onal investors participated in the financing, led ... Capital, The Wellcome Trust, HealthCare Ventures,...
(Date:11/20/2008)...e-FirstCall/ -- PAREXEL International Corporation ...cal services provider, today announced that it has...ory consulting and clinical research capabilities.... has locations throughout five important biopharma...ude Argentina, Brazil, Chile, and Mexico. This exp...
Breaking Medicine Technology:Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 2Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 3Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4Emageon Receives Best in KLAS Cardiology PACS Award 15216 1Emageon Receives Best in KLAS Cardiology PACS Award 15216 2QMed Inc Reports Year End and Fourth Quarter Results 15213 1QMed Inc Reports Year End and Fourth Quarter Results 15213 2QMed Inc Reports Year End and Fourth Quarter Results 15213 3QMed Inc Reports Year End and Fourth Quarter Results 15213 4QMed Inc Reports Year End and Fourth Quarter Results 15213 5QMed Inc Reports Year End and Fourth Quarter Results 15213 6QMed Inc Reports Year End and Fourth Quarter Results 15213 7Best Practice Database 3A Complimentary Excerpt of Scientific Publications Strategy Study 15210 1Best Practice Database 3A Complimentary Excerpt of Scientific Publications Strategy Study 15210 2NCPA Statement on Californias Delay of E Pedigree Implementation 15207 1NCPA Statement on Californias Delay of E Pedigree Implementation 15207 2
...LAINATE, Italy - July 4, 2007 - Cosmo Pharmaceutic...inary results from its,phase II/III study with CB-...ea. CB-01-11 is a broad spectrum, semi-synthetic,a...t form. Through,the use of Cosmo,s MMX(tm) technol... colon, bacteria in the gastro intestinal tract,th...
...is weeks issue of Science,researchers from the Na...(NIEHS) and Umeö University in Sweden report ...hat an enzyme called,DNA polymerase epsilon plays ...st and perhaps even humans. , The study places us ...nome instability that underlie certain environment...
Other Medicine Technology:Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III,Data with Rifamycin MMX in Infectious Diarrhea 2NIEHS Researchers Identify Enzyme Critical in DNA Replication 2NIEHS Researchers Identify Enzyme Critical in DNA Replication 3
3 mm, 130 degree upwards cutting, detachable.
Sabre 180 is a powerful niche generator.
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator.
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag.
Medicine Products: